文献速递免疫规划妇幼与学校卫生

泰国两剂麻腮风疫苗政策下儿童风疹高血清阳性率

High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy.
PubMed 文献 · Vaccine · 2021-09-21

泰国自2010年起实施两剂麻腮风(MMR)疫苗接种政策,本研究采用横断面设计,检测132名3-9岁已接种2剂疫苗儿童与424名10-18岁预期至少接种1剂疫苗青少年的风疹IgG抗体。完成2剂MMR的儿童血清阳性率为97.0%,青少年为85.4%,且抗体滴度随时间间隔延长呈负相关,提示免疫可能衰减。

要点

  • 完成2剂MMR的3-9岁儿童风疹血清阳性率达97.0%,免疫应答良好。
  • 10-18岁青少年血清阳性率为85.4%,随接种后时间延长抗体滴度下降。
  • 风疹滴度与第二剂含风疹疫苗后的时间间隔呈负相关(R=-0.30),提示免疫衰减。

核心结论

  • 两剂MMR接种在儿童中产生高风疹血清阳性率,但免疫随时间衰减,青少年血清阳性率低于儿童。

研究设计与样本

  • 泰国横断面研究,纳入132名3-9岁已接种2剂风疹疫苗的健康儿童和424名10-18岁预期至少接种1剂风疹疫苗的青少年。
  • 采用商业化酶联免疫吸附试验(ELISA)试剂盒(EUROIMMUN)检测风疹IgG抗体,血清保护定义为IgG≥10 IU/mL。
  • 儿童使用储存血清样本,青少年使用近期采集血清样本;临床试验注册号TCTR20191120001。

主要发现

  • 完成2剂MMR的儿童风疹血清阳性率为97.0%(95%CI 92.5-99.2%),青少年为85.4%(95%CI 78.8-90.6%,p<0.01)。
  • 儿童风疹几何平均滴度为38.3 IU/mL(95%CI 33.5-43.9),高于青少年的22.5 IU/mL(95%CI 19.4-25.9)。
  • 风疹滴度与第二剂含风疹疫苗后的时间间隔呈负相关(R=-0.30,p<0.01)。

关键数值与推荐

  • 血清保护阈值:风疹IgG≥10 IU/mL。
  • 儿童2剂MMR后血清阳性率97.0%(95%CI 92.5-99.2%);青少年85.4%(95%CI 78.8-90.6%,p<0.01)。
  • 几何平均滴度:儿童38.3 IU/mL(95%CI 33.5-43.9),青少年22.5 IU/mL(95%CI 19.4-25.9)。

临床怎么用

  • 支持维持两剂MMR接种以在儿童期获得高风疹免疫覆盖率。
  • 应关注接种后时间延长导致的抗体衰减,青少年期血清阳性率下降提示需评估加强免疫或监测策略。
  • 对育龄前女性等重点人群可考虑开展风疹免疫状态评估,以预防先天性风疹综合征。

局限性

  • 横断面设计无法确证个体抗体衰减的因果关系。
  • 儿童与青少年血清样本来源不同(储存样本与近期采集样本),可能影响可比性。
  • 仅检测IgG抗体水平,未评估细胞免疫及实际保护效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rubella is generally a mild disease, but infection during pregnancy can cause congenital rubella syndrome. Thailand has implemented a two-dose MMR vaccination policy since 2010. This study aimed to describe the seroprevalence rate of rubella among children and adolescents in Thailand. We conducted a cross-sectional study of 132 healthy children (aged 3-9 years) who had received 2 doses of rubella vaccine and 424 adolescents (aged 10-18 years) who were expected to receive at least 1 dose of rubella vaccine. Stored serum samples from healthy children and recently drawn serum samples from adolescents were tested for rubella IgG antibody using a commercial enzyme-linked immunosorbent assay (ELISA) kit (EUROIMMUN). Seroprotection was defined as a rubella IgG level ≥ 10 IU/mL. The rubella seroprevalence rate among children and adolescents who had 2 documented doses of MMR was 97.0% (95 %CI 92.5-99.2%) and 85.4% (95% CI 78.8-90.6%, p < 0.01) respectively. The geometric mean titer of rubella was higher in children, 38.3 (95% CI 33.5-43.9) compared to adolescents, 22.5 (19.4-25.9) IU/mL. We observed an inverse correlation between the rubella titer and time interval from the second rubella containing vaccine dose (R = -0.30, p < 0.01). A 2-dose MMR vaccination course produces a high seroprevalence of rubella immunity in children, which decreases with time, suggesting waning of immunity. Thai clinical trials registry number TCTR20191120001.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Angsuwatcharakon P, Puthanakit T, Bunjoungmanee P, et al. High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy. Vaccine. 2021. PMID: 34556367. doi:10.1016/j.vaccine.2021.08.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。